Biodesix (BDSX) to Release Earnings on Thursday

Biodesix (NASDAQ:BDSX) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $18.47 million for the quarter. Biodesix has set its FY 2025 guidance at EPS.

Biodesix (NASDAQ:BDSX) last issued its earnings results on Tuesday, May 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). Biodesix had a negative return on equity of 167.28% and a negative net margin of 54.28%. The company had revenue of $17.96 million for the quarter, compared to the consensus estimate of $19.50 million. On average, analysts expect Biodesix to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biodesix Trading Down 2.5%

BDSX stock opened at $0.38 on Thursday. The company has a debt-to-equity ratio of 3.32, a current ratio of 2.22 and a quick ratio of 2.22. Biodesix has a 1-year low of $0.17 and a 1-year high of $2.04. The business has a 50 day simple moving average of $0.31 and a two-hundred day simple moving average of $0.59. The company has a market capitalization of $55.47 million, a price-to-earnings ratio of -1.31 and a beta of 0.97.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Canaccord Genuity Group lowered their target price on shares of Biodesix from $2.50 to $1.50 and set a “buy” rating on the stock in a report on Wednesday, May 14th. William Blair reiterated a “market perform” rating on shares of Biodesix in a research note on Wednesday, May 14th. Scotiabank dropped their price objective on shares of Biodesix from $3.00 to $2.00 and set a “sector outperform” rating for the company in a report on Wednesday, May 21st. Lake Street Capital reduced their target price on Biodesix from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. Finally, Craig Hallum decreased their target price on Biodesix from $3.00 to $1.50 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1.75.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.